Denis Collins

Denis Collins is an Assistant Professor in the School of Biotechnology at Dublin City University. His research focuses on understanding HER2 and HER4 signaling pathways in cancers, particularly breast cancer, and developing novel therapeutic strategies. He explores drug resistance mechanisms, immune responses to treatments, and biomarkers for clinical outcomes. His work combines preclinical models with clinical insights to evaluate drug combinations and their efficacy.

His research interests emphasize targeted therapies, immune modulation in cancer, and the application of CRISPR/Cas9 for genetic editing in oncology. He investigates how HER family inhibitors interact with chemotherapy and immune cells, aiming to improve patient survival and reduce treatment resistance. Recent studies highlight the potential of synergistic drug pairs like neratinib-dasatinib and the role of immune checkpoint proteins (e.g., PD-L1) in predicting treatment response.

While no scientific awards are explicitly mentioned, his contributions to HER2-driven cancer research are significant. Collaborations with clinical teams and preclinical drug developers suggest a strong translational focus. No formal advisees or grant details are provided in the texts, though his publications indicate active engagement in cancer research projects.

No specific laboratories or research teams are mentioned in the provided information. His work appears to be centered on drug efficacy, biomarker discovery, and immune profiling in HER2-positive cancers.